NCT06841666View on ClinicalTrials.gov

Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

September 5, 2025

Conditions
ADHDPrimary Nocturnal Enuresis
Interventions
DRUG

Atomoxetine

Atomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.

DRUG

Placebo

Placebo identical in form and dosing schedule for six months.

All Listed Sponsors
lead

Tanta University

OTHER